Clinical Trials | May 28, 2024
Ascentage releases results from multiple clinical studies of its lead drug candidates
These abstracts report on the company's three lead drug candidates, including olverembatinib
These abstracts report on the company's three lead drug candidates, including olverembatinib
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Subscribe To Our Newsletter & Stay Updated
